Quantcast
Last updated on April 18, 2014 at 13:57 EDT

Latest BD Diagnostics Stories

2014-03-19 08:29:00

BD Veritor(TM) System for Rapid Detection of RSV Receives 510(k) Clearance and CLIA Waiver FRANKLIN LAKES, N.J., March 19, 2014 /PRNewswire/ -- BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it received 510(k) clearance and Clinical Laboratory Improvement Amendments (CLIA) waiver from the U.S. Food and Drug Administration (FDA) for nasopharyngeal swab specimens on the BD Veritor(TM) System...

2014-02-25 08:32:06

BD Veritor(TM) System for Rapid Detection of Group A Strep Receives 510(k) Clearance and CLIA Waiver FRANKLIN LAKES, N.J., Feb. 25, 2014 /PRNewswire/ -- BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it received 510(k) clearance and Clinical Laboratory Improvement Amendments (CLIA) Waiver from the U.S. Food and Drug Administration (FDA) for the BD Veritor(TM) System for Rapid Detection of...

2014-02-04 08:32:53

-- Raises the bottom end of full fiscal year 2014 revenue and earnings ranges for guidance. FRANKLIN LAKES, N.J., Feb. 4, 2014 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $2.0 billion for the first fiscal quarter ended December 31, 2013, representing an increase of 6.0 percent from the prior-year period, or 6.7 percent on a foreign currency-neutral basis. Revenue growth was...

2014-01-13 08:27:46

BD MAX(TM) MRSA XT Assay with eXTended Detection Technology Receives FDA Clearance BALTIMORE, Jan. 13, 2014 /PRNewswire/ -- BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today it has received FDA clearance to market the BD MAX(TM) MRSA XT Assay for use on the fully-automated BD MAX(TM) System. This is the second assay from BD Diagnostics capable of detecting newly emerging MRSA strains with the...

2014-01-07 08:30:54

Advances BD Diagnostics' Point-of-Care Strategy FRANKLIN LAKES, N.J., Jan. 7, 2014 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it has acquired Alverix, Inc., a privately-held diagnostic instrument company known for its optoelectronics expertise. Since 2008, BD and Alverix have collaborated in the point-of-care diagnostic market with the design and development of the BD Veritor(TM) System, which has...

2013-12-03 08:32:48

BD MAX(TM) StaphSR Assay with eXTended Detection Technology Receives FDA Clearance BALTIMORE, Dec. 3, 2013 /PRNewswire/ -- BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received FDA clearance to market the BD MAX(TM) StaphSR Assay for use on the fully-automated BD MAX(TM) System. The assay, with eXTended Detection Technology, accurately detects Staphylococcus aureus (SA) and...

2013-11-05 08:32:48

- Reports adjusted diluted earnings per share from continuing operations of $5.81 for the full fiscal year, in-line with the Company's expectations. Reported diluted earnings per share from continuing operations were $4.67. FRANKLIN LAKES, N.J., Nov. 5, 2013 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $2.1 billion for the fourth fiscal quarter ended September 30, 2013,...

2013-10-16 04:21:44

Expansion of Product Portfolio for Microbiological Analyses in the Lab GOETTINGEN, Germany and BALTIMORE, Oct. 16, 2013 /PRNewswire/ -- Sartorius Stedim Biotech (SSB), a leading international pharma and biotech supplier, and BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a collaboration to develop, manufacture and market various ready-to-use, prefilled media products for microbiological...

2013-08-27 08:27:40

New Molecular Test Available to Diagnose Trichomonas vaginalis in Asymptomatic and Symptomatic Females BALTIMORE, Aug. 27, 2013 /PRNewswire/ -- BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today the U.S. Food and Drug Administration clearance and launch of the BD ProbeTec(TM) Trichomonas vaginalis Q(x) Amplified DNA Assay for the direct qualitative detection of T. vaginalis DNA in endocervical and...

2013-08-01 08:31:48

-- Reports solid third fiscal quarter revenues of $2.053 billion, an increase of 3.6 percent, or 5.1 percent on a foreign currency-neutral basis. FRANKLIN LAKES, N.J., Aug. 1, 2013 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $2.053 billion for the third fiscal quarter ended June 30, 2013, representing an increase of 3.6 percent from the prior-year period, or 5.1 percent on a...